Immunoproteomics approach for prediction of antigenic epitope of Tertiapin from Apis mellifera

The bee venom is used for treating a wide variety of disease conditions. It has also beenfound to be a strong immunological agent, stimulating the body's protective mechanisms againstdisease. The major treatment is gene therapy or recombinant DNA vaccines involved targeting multipleantigenic components to direct and empower the immune system to protect the host from infection.Limitation of therapy to the treatment of patients suffering from various adverse reaction andcontraindications are always experienced. Tertiapin is a neurotoxin from the honeybee venom. Itinteracts specifically with calmodulin in the presence of Ca2+. Antigenic epitopes on Tertiapin protein ofApis mellifera (honey bee) is important determinants sites for protection against disorders. As ourknowledge of the immune responses to a protein antigen progressed, it became clear that the wholeprotein is not necessary for raising the immune response, but small segments (NCNRIIIPHMCWK, 4-16)of tertiapin protein called the antigenic determinants or the epitopes are sufficient for eliciting the desiredimmune response. Immunization cassettes should be capable of immunizing of broad immunity againstboth humoral and cellular epitope thus giving vaccines the maximum ability to deal with Tertiapin proteinof Apis mellifera immune escape. We have predicted a successful immunization strategy.